Nonsteroidal MRAs in CKD and T2D: Current knowledge and practical insights

Bayer AG |

Chair: Peter Rossing (DNK)

18:45 – 18:50Welcome and introductionsPeter Rossing (DNK)
18:50 – 19:00The importance of guidelines for identification and treatment of CKD in T2D: Where are we nowJanet McGill (USA)
19:00 – 19:20The cardiorenal benefits of nonsteroidal MRAs: Insights from across the CKD in T2D patient spectrumPeter Rossing (DNK)
19:20 – 19:35Finerenone in clinical practice: Approaches for optimising the patient experienceMagnus Löndahl (SWE)
19:35 – 19:45Q&A and closePeter Rossing (DNK)